Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


Our top-notch dedicated system is used to design specialised libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
P15144

UPID:
AMPN_HUMAN

ALTERNATIVE NAMES:
Alanyl aminopeptidase; Aminopeptidase M; Microsomal aminopeptidase; Myeloid plasma membrane glycoprotein CD13; gp150

ALTERNATIVE UPACC:
P15144; Q16728; Q6GT90; Q8IUK3; Q8IVH3; Q9UCE0

BACKGROUND:
Aminopeptidase N, with alternative names such as Microsomal aminopeptidase and gp150, is a broad specificity enzyme crucial for peptide digestion and modulation of various biological processes. It is implicated in the cleavage of peptides from proteins, processing of peptide hormones like angiotensin, and involvement in immune responses. Additionally, it acts as a receptor for human coronavirus 229E and mediates Human cytomegalovirus infection.

THERAPEUTIC SIGNIFICANCE:
The exploration of Aminopeptidase N's functions offers promising avenues for therapeutic intervention. Given its significant role in peptide processing, immune system modulation, and as a viral receptor, targeting Aminopeptidase N could lead to novel treatments for a range of diseases, including viral infections and disorders related to peptide hormone imbalances.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.